ERGOFLEX(TM) Joint Pain Study Published Online in Preventive Medicine
Oxis International Inc.
28.03.2012 08:30
---------------------------------------------------------------------------
OXIS International's Proprietary ERGOFLEX Product Demonstrates Significant
Improvement in Pain and Range of Motion -- Product Launch 2nd Quarter 2012
BEVERLY HILLS, Calif., 2012-03-28 08:30 CEST (GLOBE NEWSWIRE) --
OXIS International, Inc. (OXIS.OB) (Paris:OXI) announced today that a Joint
Pain and Mobility study demonstrating highly significant short and long-term
benefits for joint health using its Patent Pending ERGOFLEX(tm) with proprietary
EGT(tm) (99% pure L-ergothioneine) complex, has been published in the
peer-reviewed journal, Preventive Medicine. EGT is a natural anti-oxidant,
anti-inflammatory nutrient, required by humans as well as all animals, but only
available through diet until now. EGT is the only known intelligent
anti-oxidant to be actively transported into cells under stress. ERGOFLEX is
the first dietary supplement to incorporate EGT and the only joint health
complex containing this unique intelligent antioxidant. ERGOFLEX is
specifically formulated to support the body's natural ability to fight the pain
of joint inflammation while providing support for the structural integrity and
lubrication of joints.
The study, carried out by NIS Laboratories in Klamath Falls, Oregon and
presented by Gitte Jensen, PhD at the First International Congress on EGT, in
July 2011 (www.ergocongress.com) was co-authored by Dr. Okezie Aruoma, PhD,
DSc, MBA, is the world's leading expert on EGT. 'EGT not only protects vital
organs against the oxidative stress but conserves the consumption of endogenous
glutathione and vitamin E,' said Dr. Aruoma.
'ERGOFLEX, our first EGT-based product is an important entrant in the
multi-billion dollar U.S. market for non-prescription joint health products,'
said David Saloff, CEO of OXIS International. 'Most joint pain products only
address symptoms. ERGOFLEX targets oxidative stress and inflammation, well
recognized underlying issues in joint ailments,' said Bernie Landes, President
of OXIS.
OXIS CEO David Saloff added, 'Over the coming months we plan to introduce
specific EGT based products that address key health goals of not only an aging
population of baby boomers, but also a younger audience seeking to maintain
their youthful good health.'
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation
associated with damage from free radical and reactive oxygen species (ROS). The
company holds the rights to several therapeutic classes of compounds in the
area of oxidative stress, including EGT(tm) (99% pure L-ergothioneine), known as
the intelligent antioxidant.
CONTACT: David Saloff
424-248 2311
David@Oxis.com
News Source: NASDAQ OMX
28.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Oxis International Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6918294025
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Oxis International Inc.
28.03.2012 08:30
---------------------------------------------------------------------------
OXIS International's Proprietary ERGOFLEX Product Demonstrates Significant
Improvement in Pain and Range of Motion -- Product Launch 2nd Quarter 2012
BEVERLY HILLS, Calif., 2012-03-28 08:30 CEST (GLOBE NEWSWIRE) --
OXIS International, Inc. (OXIS.OB) (Paris:OXI) announced today that a Joint
Pain and Mobility study demonstrating highly significant short and long-term
benefits for joint health using its Patent Pending ERGOFLEX(tm) with proprietary
EGT(tm) (99% pure L-ergothioneine) complex, has been published in the
peer-reviewed journal, Preventive Medicine. EGT is a natural anti-oxidant,
anti-inflammatory nutrient, required by humans as well as all animals, but only
available through diet until now. EGT is the only known intelligent
anti-oxidant to be actively transported into cells under stress. ERGOFLEX is
the first dietary supplement to incorporate EGT and the only joint health
complex containing this unique intelligent antioxidant. ERGOFLEX is
specifically formulated to support the body's natural ability to fight the pain
of joint inflammation while providing support for the structural integrity and
lubrication of joints.
The study, carried out by NIS Laboratories in Klamath Falls, Oregon and
presented by Gitte Jensen, PhD at the First International Congress on EGT, in
July 2011 (www.ergocongress.com) was co-authored by Dr. Okezie Aruoma, PhD,
DSc, MBA, is the world's leading expert on EGT. 'EGT not only protects vital
organs against the oxidative stress but conserves the consumption of endogenous
glutathione and vitamin E,' said Dr. Aruoma.
'ERGOFLEX, our first EGT-based product is an important entrant in the
multi-billion dollar U.S. market for non-prescription joint health products,'
said David Saloff, CEO of OXIS International. 'Most joint pain products only
address symptoms. ERGOFLEX targets oxidative stress and inflammation, well
recognized underlying issues in joint ailments,' said Bernie Landes, President
of OXIS.
OXIS CEO David Saloff added, 'Over the coming months we plan to introduce
specific EGT based products that address key health goals of not only an aging
population of baby boomers, but also a younger audience seeking to maintain
their youthful good health.'
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation
associated with damage from free radical and reactive oxygen species (ROS). The
company holds the rights to several therapeutic classes of compounds in the
area of oxidative stress, including EGT(tm) (99% pure L-ergothioneine), known as
the intelligent antioxidant.
CONTACT: David Saloff
424-248 2311
David@Oxis.com
News Source: NASDAQ OMX
28.03.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Oxis International Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6918294025
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------